Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Aadi Bioscience, Inc. AADI
$6.99
+$0.09 (1.30%)
На 18:04, 12 мая 2023
Ранг: 3
Ключевые показатели
-
Marketcap
209425090.00000000
-
week52high
17.27
-
week52low
6.80
-
Revenue
15216000
-
P/E TTM
-4
-
Beta
0.00000000
-
EPS
-2.62000000
-
Last Dividend
0.00000000
-
Next Earnings Date
10 мая 2023 г. в 12:30
Описание компании
Aadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. The company was incorporated in 2007 and is headquartered in Pacific Palisades, California.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| HC Wainwright & Co. | Buy | Buy | 11 апр 2022 г. |
| Jefferies | Buy | 11 янв 2022 г. | |
| HC Wainwright & Co. | Buy | Buy | 24 ноя 2021 г. |
| Cowen & Co. | Outperform | 01 окт 2021 г. | |
| Ladenburg Thalmann | Buy | 14 сент 2021 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Desai Neil | A | 150000 | 150000 | 03 янв 2023 г. |
| Delaney Brendan | A | 150000 | 150000 | 03 янв 2023 г. |
| Castelein Caley | A | 499998 | 240000 | 26 сент 2022 г. |
| Delaney Brendan | A | 20000 | 20000 | 26 сент 2022 г. |
| Dalal Anupam | A | 1849402 | 320000 | 26 сент 2022 г. |
| Giacobello Scott M. | A | 20000 | 20000 | 26 сент 2022 г. |
| Aghazadeh Behzad | A | 3471752 | 1260000 | 22 сент 2022 г. |
| Reeve Emma | A | 18573 | 18573 | 15 июн 2022 г. |
| Aghazadeh Behzad | A | 18573 | 18573 | 15 июн 2022 г. |
| Castelein Caley | A | 18573 | 18573 | 15 июн 2022 г. |
Новостная лента
Aadi Bioscience, Inc. (AADI) Upgraded to Buy: What Does It Mean for the Stock?
Zacks Investment Research
06 янв 2023 г. в 13:33
Aadi Bioscience, Inc. (AADI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Aadi Bioscience, Inc. (AADI) Q3 2022 Earnings Call Transcript
Seeking Alpha
09 ноя 2022 г. в 15:30
Aadi Bioscience, Inc. (NASDAQ:AADI ) Q3 2022 Earnings Conference Call November 9, 2022 8:30 AM ET Company Participants Marcy Graham - Senior Vice President of Investor Relations & Corporate Communications Neil Desai - President & Chief Executive Officer Brendan Delaney - Chief Operating Officer Loretta Itri - Chief Medical Officer Scott Giacobello - Chief Financial Officer Conference Call Participants Roger Song - Jefferies Boris Peaker - Cowen Joseph Catanzaro - Piper Sandler Operator Good day and thank you for standing by. Welcome to the Aadi Bioscience, Inc. Third Quarter Earnings Conference Call.
Aadi Bioscience: Taking mTOR Inhibition To The Next Level
Seeking Alpha
21 сент 2022 г. в 10:04
Shares have lost half their value since reverse merger with Aerpio Pharmaceuticals. Aadi aims to deliver on the broad potential of mTOR inhibition via nab technology to achieve wide therapeutic index and greater target suppression.
Aadi Bioscience, Inc. (AADI) CEO Neil Desai on Q2 2022 Results - Earnings Call Transcript
Seeking Alpha
10 авг 2022 г. в 14:40
Aadi Bioscience, Inc. (NASDAQ:AADI ) Q2 2022 Earnings Conference Call August 10, 2022 8:30 AM ET Company Participants Marcy Graham - SVP of IR and Corporate Communications Neil Desai - President and CEO Brendan Delaney - COO Loretta Itri - Chief Medical Officer Scott Giacobello - CFO Conference Call Participants Boris Peaker - Cowen Jiale Song - Jefferies Robert Burns - H.C. Wainwright Operator Good day and thank you for standing by.
Aadi Bioscience to Present at the H.C. Wainwright Global Investment Conference
GlobeNewsWire
18 мая 2022 г. в 07:00
LOS ANGELES, May 18, 2022 (GLOBE NEWSWIRE) -- Aadi Bioscience, Inc. (Nasdaq: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, today announced that Founder, Chief Executive Officer and President, Neil Desai, Ph.D., and senior members of Aadi's executive team will participate virtually in the H.C. Wainwright Global Investment Conference, to be held in person and virtually May 23-26, 2022 in Miami, FL.